{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:34:53Z","timestamp":1793853293029,"version":"4.6.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017547","name":"Spark Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cgh.2022.12.040","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T02:17:09Z","timestamp":1677637029000},"page":"2088-2099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9161-5892","authenticated-orcid":false,"given":"Robert J.","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar S.","family":"Bjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul J.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.12.040_bib1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bjornsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.040_bib3","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and etiology of drug-induced liver injury in mainland China","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.040_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MPG.0000000000002383","article-title":"Antimicrobials and antiepileptics are the leading causes of idiosyncratic drug-induced liver injury in American children","volume":"69","author":"DiPaola","year":"2019","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2022.12.040_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.yrtph.2018.01.018","article-title":"Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury","volume":"94","author":"George","year":"2018","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.cgh.2022.12.040_bib6","article-title":"American Association for the Study of Liver Diseases Practice Guidance on drug, herbal, and dietary-supplement-induced liver injury","author":"Fontana","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib7","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/hep.27317","article-title":"Liver injury from herbals and dietary supplement in the US Drug-Induced Liver Injury Network","volume":"60","author":"Navarro","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep4.1346","article-title":"The contents of herbal and dietary supplements implicated in liver injury in the United States are frequently mislabelled","volume":"3","author":"Navarro","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2022.12.040_bib9","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/hep.31538","article-title":"HLA-B \u2217 35:01 and green-tea induced liver injury","volume":"73","author":"Hoofnagle","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/liv.14393","article-title":"Liver injury due to Ashwagandha. A case series from Iceland and the U.S. Drug-Induced Liver Injury Network","volume":"40","author":"Bj\u00f6rnsson","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2022.12.040_bib11","doi-asserted-by":"crossref","unstructured":"Vuppalanchi R, Bonkovsky HL, Ahmad J, et\u00a0al. Garcinia cambogia either alone or in combination with green tea, causes moderate to severe liver injury. Clin Gastroenterol Hepatol. Published online June 20, 2022. https:\/\/doi.org\/10.1016\/j.cgh.2021.08.015.","DOI":"10.1016\/j.cgh.2021.08.015"},{"key":"10.1016\/j.cgh.2022.12.040_bib12","article-title":"Liver injury associated with turmeric, a growing problem: ten cases from the Drug-Induced Liver Injury Network","author":"Halegoua-DeMarzio","year":"2022","journal-title":"Am J Med December"},{"key":"10.1016\/j.cgh.2022.12.040_bib13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/apt.15211","article-title":"Severe and protracted cholestasis in 44 young mean taking bodybuilding supplements: assessment of genetic, clinical, and chemical risk factors","volume":"49","author":"Stolz","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.12.040_bib14","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1016\/j.cgh.2021.01.011","article-title":"Herbal and dietary supplements-induced liver injury in Latin America: experience from the LATINDILI Network","volume":"20","author":"Bessone","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.12.040_bib15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jhep.2021.12.013","article-title":"Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study","volume":"76","author":"Chalasani","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.12.040_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2021.08.024","article-title":"Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.12.040_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors","volume":"115","author":"Miller","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.12.040_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12328-020-01287-1","article-title":"A\u00a0case with life-threatening secondary sclerosing cholangitis caused by nivolumab","volume":"14","author":"Yoshikawa","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.12.040_bib19","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/hep4.1959","article-title":"Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports","volume":"6","author":"Bj\u00f6rnsson","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2022.12.040_bib20","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/hep4.1904","article-title":"Tinospora cofdifolia (Giloy)\u2013induced liver injury during the COVID-19 pandemic: multicenter nationwide study from India","volume":"6","author":"Kukkarni","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2022.12.040_bib21","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1007\/s10620-022-07504-w","article-title":"Autoimmune hepatitis-like syndrome following COVID-19 vaccination: a systematic review of the literature","volume":"67","author":"Chow","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2022.12.040_bib22","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/hep.32572","article-title":"Liver injury after SARS-CoV-2 vaccination: features of immune mediated hepatitis, role of corticosteroid therapy, and outcome","volume":"76","author":"Efe","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108426","article-title":"Liver injury associated with a popular opioid-like product: experience from the US DILIN and a review of the literature","volume":"218","author":"Ahmad","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.cgh.2022.12.040_bib25","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical practice Guidelines. Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.12.040_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"DILIN prospective study: rationale, design, and conduct","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2022.12.040_bib27","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.14309\/ajg.0000000000001869","article-title":"Incidence of hepatitis E infection in American patients with suspected drug-induced liver injury is low and declining: the DILIN Prospective study","volume":"117","author":"Fontana","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.12.040_bib28","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1007\/s10620-019-05591-w","article-title":"Importance of hepatitis C virus RNA testing in patients with suspected drug-induced liver injury","volume":"64","author":"Ahmad","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2022.12.040_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2022.08.012","article-title":"Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease: an analysis of pivotal clinical trials","volume":"81","author":"Alpers","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cgh.2022.12.040_bib30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.26709","article-title":"Hepatic histological findings in suspected drug-induced liver injury. Systematic evaluation and clinical associations","volume":"59","author":"Kleiner","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib31","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2021.12.043","article-title":"Value of liver biopsy in the diagnosis of DILI","volume":"76","author":"Ahmad","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.12.040_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports","volume":"63","author":"Bjornsson","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1053\/j.gastro.2014.12.007","article-title":"Discrepancies in liver disease labelling in the package inserts of commonly prescribed medications","volume":"149","author":"Bjornsson","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.040_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.drudis.2021.09.009","article-title":"A\u00a0systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labelling reveals discrepancies","volume":"27","author":"Wu","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cgh.2022.12.040_bib35","first-page":"14","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"27","author":"Danan","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cgh.2022.12.040_bib36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hep.32327","article-title":"A\u00a0revised electronic version of RUCAM for the diagnosis of drug induced liver injury","volume":"76","author":"Hayashi","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib37","article-title":"Comparison of Roussel-Uclaf causality assessment method (RUCAM) versus revised electronic causality assessment method (RECAM): analysis of 100 cases from an Indian Registry","volume":"76","author":"Devarbhavi","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/hep.30660","article-title":"HLA-B \u2217 35:01 allele is a potential biomarker for predicting polygonum multiforum induced liver injury in humans","volume":"70","author":"Li","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib39","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1053\/j.gastro.2019.01.034","article-title":"A\u00a0missense variant in PTPN22 is a risk factor for drug-induced liver injury","volume":"156","author":"Cirulli","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.040_bib40","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/hep.29802","article-title":"Candidate biomarkers for the diagnosis and prognosis of DILI: an international collaborative effort","volume":"69","author":"Church","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib41","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2217\/bmm-2021-0222","article-title":"Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a phase II trial","volume":"15","author":"Wagner","year":"2021","journal-title":"Biomark Med"},{"key":"10.1016\/j.cgh.2022.12.040_bib42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/toxsci\/kfab003","article-title":"Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans","volume":"181","author":"Llewellyn","year":"2021","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.cgh.2022.12.040_bib43","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1053\/j.gastro.2020.10.002","article-title":"High-fidelity drug-induced liver injury screen using human pluripotent stem cell-derived organoids","volume":"160","author":"Shinozawa","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.040_bib44","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.040_bib45","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.040_bib46","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/hep.29283","article-title":"Death and liver transplantation within 2 years of onset of drug-induced liver injury","volume":"66","author":"Hayashi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2014.03.045","article-title":"DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset","volume":"147","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.040_bib48","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/ajg.2017.215","article-title":"Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians","volume":"112","author":"Chalasani","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.12.040_bib49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2021.01.029","article-title":"Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry","volume":"75","author":"Stephens","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.12.040_bib50","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1053\/j.gastro.2019.07.006","article-title":"Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected DILI","volume":"157","author":"Ghabril","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.040_bib51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with DILI","volume":"147","author":"Robles-Diaz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.040_bib52","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/cts.12868","article-title":"Effects of bardoxolone methyl on hepatic enzymes in patients with type 2 diabetes mellitus and stage 4 CKD","volume":"14","author":"Lewis","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.cgh.2022.12.040_bib53","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/ajg.2015.283","article-title":"Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug-induced liver injury","volume":"110","author":"Fontana","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.12.040_bib54","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jhep.2016.05.003","article-title":"Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury","volume":"65","author":"Medina-Caliz","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.12.040_bib55","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jhep.2021.10.011","article-title":"Long-term sequelae of drug-induced liver injury","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.12.040_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.820724","article-title":"Role of corticosteroids in drug-induced liver injury: a systematic review","volume":"13","author":"Bj\u00f6rnsson","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cgh.2022.12.040_bib57","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.26678","article-title":"Steroid use in ALF","volume":"59","author":"Karkhanis","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib58","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/apt.15413","article-title":"Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy","volume":"50","author":"Tsung","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.12.040_bib59","doi-asserted-by":"crossref","unstructured":"Swanson LA, Kassab I, Tsung I, et\u00a0al. Liver injuring during durvulumab-based immunotherapy is associated with poorer patient survival: a retrospective analysis. Front Oncol. Published online October 24, 2022. https:\/\/doi.org\/10.3389\/fonc.2022.984940","DOI":"10.3389\/fonc.2022.984940"},{"key":"10.1016\/j.cgh.2022.12.040_bib60","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4254\/wjh.v14.i7.1269","article-title":"Checkpoint inhibitor-induced hepatoxicity: role of liver biopsy and management approach","volume":"14","author":"Bessone","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.cgh.2022.12.040_bib61","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cgh.2022.12.040_bib62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.6004\/jnccn.2022.7011","article-title":"The role of tissue biopsy in the management of immune checkpoint inhibitor toxicity","volume":"20","author":"Fecher","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.cgh.2022.12.040_bib63","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2009.06.006","article-title":"Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure","volume":"137","author":"Lee","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.040_bib64","doi-asserted-by":"crossref","first-page":"e3377","DOI":"10.1093\/cid\/ciaa1255","article-title":"A\u00a0randomized controlled trial of intravenous N-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury","volume":"73","author":"Moosa","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cgh.2022.12.040_bib65","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/hep.26001","article-title":"Pediatric Acute Liver Failure Study Group. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial","volume":"57","author":"Squires","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.12.040_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.744488","article-title":"Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review","volume":"12","author":"Robles-Diaz","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cgh.2022.12.040_bib67","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1345\/aph.1P135","article-title":"L-carnitine for acute valproic acid overdose: a systematic review of published cases","volume":"44","author":"Perrott","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cgh.2022.12.040_bib68","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/liv.15189","article-title":"Leflunomide induced liver injury: differences in characteristics and outcomes in Indian and US registries","volume":"42","author":"Devarbhavi","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2022.12.040_bib69","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cgh.2022.12.040_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.785790","article-title":"Novel therapies for the treatment of drug-induced liver injury: a systematic review","volume":"12","author":"Benic","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cgh.2022.12.040_bib71","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1586\/17474124.2016.1127756","article-title":"Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review","volume":"10","author":"Stine","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.12.040_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105404","article-title":"Prevention and management of idiosyncratic drug-induced liver injury: systematic review and meta-analysis of randomized clinical trials","volume":"164","author":"Niu","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cgh.2022.12.040_bib73","doi-asserted-by":"crossref","first-page":"617","DOI":"10.14309\/ajg.0000000000001655","article-title":"Secular trends in severe idiosyncratic drug-induced liver injury in North America: an update from the ALFSG Registry","volume":"117","author":"Rao","year":"2022","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652300160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652300160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:42:10Z","timestamp":1761543730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235652300160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S154235652300160X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.12.040","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.12.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute","name":"copyright","label":"Copyright"}]}}